findmyKOL

Nathan Radcliffe, MD

Enriched profile

Associate Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai · Icahn School of Medicine at Mount Sinai

ORCIDNPI
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyOphthalmologyFocusGlaucoma
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Nathan Radcliffe is Associate Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai at Icahn School of Medicine at Mount Sinai. OpenAlex indexes 177 publications with 2,726 citations (h-index 28); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 31 Aug 2026

Nathan Radcliffe, MD, is Associate Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai. The public record shows 177 publications with 2,726 citations (h-index 28), centered on Glaucoma. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 45 companies.

  • Most recent indexed publication: 2025 · Clinical ophthalmology (Auckland, N.Z.)
  • Top research focus: Glaucoma
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 45 companies

Generated from the cited public record · current as of 31 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Glaucoma3 trialsComa3 trialsHypertension2 trialsOcular Hypertension2 trialsCataract1 trial

Research focus

OpenAlex concept fingerprint
Glaucoma

Drugs & molecules

across trials, industry payments and publications
Dexycugeneric · DexamethasoneClinical trialsIndustry payments14Publications1Xelprosgeneric · LatanoprostClinical trialsIndustry payments5Publications1Durystageneric · BimatoprostClinical trialsIndustry payments295Publications

Works with

trial sponsors and companies reporting payments
Alcon Vision LLCClinical trialsIndustry payments467Abbvie Inc.Clinical trialsIndustry payments236Allergan, Inc.Clinical trialsIndustry payments199

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
177publications

Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.

2,726citations

Total citations across indexed works.

28h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials
45companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 31 Aug 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 31 Aug 2026

45 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    84%
    Prostaglandin Analog36.2%
    Latanoprost79%Lumigan18%Iyuzeh2%Travoprost1%
    Part D<11 patients
    Carbonic Anhydrase Inhibitor21.8%
    Dorzolamide-Timolol65%Simbrinza11%Acetazolamide Er9%Dorzolamide Hcl9%Brinzolamide4%Acetazolamide2%
    Part D504 patients
  • Cancer & immunology

    4.5%
    Calcineurin inhibitor4.5%
    Restasis91%Cyclosporine7%Vevye2%
    Part D<11 patients
  • Cardiovascular

    4.3%
    Beta blocker4.3%
    Timolol Maleate90%Betaxolol Hcl10%
    Part D145 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)3.5% facility · 96.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 31 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 31 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/nathan-radcliffe-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • Other

    drradcliffe.com

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →drradcliffe.com
  • X / Twitter

    x.com/n8radcliffe

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/glaucomatoday/p/C33DcAKtEjB

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com
  • Other

    eyetube.net/podcasts/gt-the-podcast

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyetube.net
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 31 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
2 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
1 more award behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.